Juno Therapeutics Inc (NASDAQ:JUNO) CEO Hans Edgar Bishop sold 270,250 shares of the company’s stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $46.17, for a total value of $12,477,442.50. Following the completion of the sale, the chief executive officer now owns 2,772,679 shares in the company, valued at approximately $128,014,589.43. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of Juno Therapeutics Inc (NASDAQ:JUNO) traded up $0.15 during midday trading on Monday, reaching $85.84. The company’s stock had a trading volume of 2,971,635 shares, compared to its average volume of 6,280,425. The stock has a market cap of $9,810.00, a P/E ratio of -25.32 and a beta of 3.42. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.77 and a quick ratio of 4.77. Juno Therapeutics Inc has a 12 month low of $19.62 and a 12 month high of $86.28.
Several equities analysts have recently weighed in on the company. JPMorgan Chase & Co. restated a “hold” rating on shares of Juno Therapeutics in a research report on Thursday, January 11th. Raymond James Financial restated a “buy” rating on shares of Juno Therapeutics in a research report on Thursday, January 11th. Wells Fargo & Co reaffirmed a “market perform” rating and issued a $63.00 price target (up previously from $54.00) on shares of Juno Therapeutics in a report on Wednesday, January 17th. Barclays cut Juno Therapeutics from an “overweight” rating to an “equal weight” rating and increased their price target for the company from $55.00 to $87.00 in a report on Wednesday, January 24th. Finally, Maxim Group reaffirmed a “buy” rating and issued a $56.00 price target on shares of Juno Therapeutics in a report on Thursday, November 2nd. Two research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and three have given a buy rating to the company’s stock. Juno Therapeutics has a consensus rating of “Hold” and an average target price of $51.20.
A number of hedge funds and other institutional investors have recently made changes to their positions in JUNO. The Manufacturers Life Insurance Company lifted its holdings in Juno Therapeutics by 7.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 228 shares during the last quarter. Advisor Group Inc. increased its position in shares of Juno Therapeutics by 141.1% during the third quarter. Advisor Group Inc. now owns 2,459 shares of the biopharmaceutical company’s stock worth $109,000 after purchasing an additional 1,439 shares in the last quarter. QS Investors LLC acquired a new position in Juno Therapeutics in the 2nd quarter valued at about $135,000. Bronfman E.L. Rothschild L.P. increased its position in Juno Therapeutics by 27,376.9% in the 3rd quarter. Bronfman E.L. Rothschild L.P. now owns 3,572 shares of the biopharmaceutical company’s stock valued at $160,000 after acquiring an additional 3,559 shares during the period. Finally, State of Alaska Department of Revenue acquired a new position in Juno Therapeutics in the 4th quarter valued at about $173,000. 68.90% of the stock is owned by institutional investors.
Juno Therapeutics Company Profile
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.